keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonates

keyword
https://www.readbyqxmd.com/read/29156848/nomograms-for-prognostic-factors-of-spinal-giant-cell-tumor-combining-traditional-clinical-characteristics-with-inflammatory-biomarkers-after-gross-total-resection
#1
Jialin Li, Bo Li, Pingting Zhou, Jian Zhao, Zhipeng Wu, Xinghai Yang, Haifeng Wei, Tianrui Chen, Jianru Xiao
Giant cell tumor (GCT) of bone is a common primary bone tumor, which exhibits local aggressiveness and recurrent potential, especially for the spinal lesion. Increasing evidence indicates that inflammation plays a vital role in tumorigenesis and progression. The prognostic value of inflammatory biomarkers in GCT has not been established. A retrospective analysis was conducted in patients with spinal GCT in Changzheng Hospital Orthopedic Oncological Center (CHOOC) between January 2005 and October 2015 and 129 patients were identified eligible...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29155533/conservative-prosthetic-rehabilitation-of-medication-related-osteonecrosis-of-the-jaw-mronj
#2
Alexandra Johanna Leven, Antony J Preston
Osteonecrosis of the jaw associated with bisphosphonates and other medications is a growing problem facing dentists. It can have a significant and debilitating impact upon patients. Various treatment options ranging from surgical intervention to management with antibiotics and analgesics have been proposed. This article presents one method of conservative treatment and prosthetic rehabilitation in a patient with ongoing BRONJ of the maxilla unsuitable for surgical management. Clinical relevance: Dentists need to be able to identify patients who are at risk of developing BRONJ and have an awareness of the appropriate management as well as potential oral rehabilitation options for these patients...
December 2016: Dental Update
https://www.readbyqxmd.com/read/29154388/systematic-review-of-the-effect-of-denosumab-on-children-with-osteogenesis-imperfect-showed-inconsistent-findings
#3
Guowei Li, Yanling Jin, Mitchell A H Levine, Heike Hoyer-Kuhn, Leanne Ward, Jonathan D Adachi
Osteogenesis imperfecta (OI) is a rare, inherited disorder characterised by increased bone fragility, reduced bone mass and often short stature. Most cases are due to mutations in one of the two genes encoding collagen type-1 - COL1A1 and COL1A2 (1) - and the signs and symptoms vary substantially with the disease severity. The risk of fractures is 100 times higher than the general population, even in patients with mild OI. Bisphosphonates are the current standard pharmacotherapy for managing and treating patients with severe OI, but concerns about their long-term safety have been raised (1)...
November 20, 2017: Acta Paediatrica
https://www.readbyqxmd.com/read/29153714/polyphosphonate-ligands-from-synthesis-to-design-of-hybrid-pegylated-nanoparticles-toward-phototherapy-studies
#4
Maelle Monteil, Hanane Moustaoui, Gennaro Picardi, Fatima Aouidat, Nadia Djaker, Marc Lamy de La Chapelle, Marc Lecouvey, Jolanda Spadavecchia
The use of phosphonate ligands to modify the nanoparticle (NPs) surface has attracted a strong interest in the last years for the design of highly functional hybrid materials. Here, we applied a methodology to synthesize bisphosphonates having functionalized PEG side chains with a specific length in order to design a novel class of hybrid nanomaterials composed by tetraphosphonate-complex-gold COOH-terminated PEG-coated NPs (Bis-PO-PEG-AuNPs). The synthetic approach consist in three steps: (1) Complexation between new phosphonate ligands (Bis PO) and tetrachloroauric acid (HAuCl4) to form gold clusters; (2) adsorption of COOH-terminated PEG molecules (PEG) onto Bis PO-Au complex; (3) reduction of metal ions in that vicinity, growth of gold particles and colloidal stabilization...
November 2, 2017: Journal of Colloid and Interface Science
https://www.readbyqxmd.com/read/29150425/amino-bisphosphonates-%C3%AE-%C3%AE-t-cells-and-their-roles-in-rheumatoid-arthritis
#5
Wen-Xiu Mo, Shan-Shan Yin, Hua Chen, Xuan Zhang
No abstract text is available yet for this article.
November 17, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29146440/clodronate-a-vesicular-atp-release-blocker
#6
REVIEW
Yoshinori Moriyama, Masatoshi Nomura
Clodronate is a first-generation bisphosphonate used worldwide for antiresorptive therapy for osteoporosis. Although clodronate is analgesic in nature, its mechanism and efficacy were unknown for some time. Recently, clodronate was identified as a selective and potent inhibitor for vesicular nucleotide transporter (VNUT), a transporter responsible for vesicular storage of ATP. Clodronate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain following blockade of purinergic chemical transmission...
November 13, 2017: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/29146093/treatment-status-and-radiographic-features-of-patients-with-atypical-femoral-fractures
#7
Hiroshi Hagino, Naoto Endo, Tetsuji Yamamoto, Atsushi Harada, Jun Iwamoto, Naoki Kondo, Tasuku Mashiba, Satoshi Mori, Junichi Nakamura, Seiji Ohtori, Akinori Sakai, Junichi Takada, Yoshiharu Kato
BACKGROUND: The Japanese Orthopaedic Association (JOA) has been surveying approximately 3000 orthopedic surgery hospitals and clinics with inpatient facilities nationwide to collect information on atypical femoral fractures (AFFs) and patient characteristics since 2010. The present study aims to examine radiographic images and clarify the relationship between radiographic and patient characteristics of patients with AFF and treatment status. METHODS: The study involved 1996 facilities certified as clinical training sites by the JOA and 912 clinics with inpatient facilities affiliated with the Japanese Clinical Orthopaedic Association (JCOA)...
November 13, 2017: Journal of Orthopaedic Science: Official Journal of the Japanese Orthopaedic Association
https://www.readbyqxmd.com/read/29144808/osteoporotic-fractures-during-bisphosphonate-drug-holiday-fractures-bisphosphonate-drug-holidays
#8
Brittany Bindon, William Adams, Neelam Balasubramanian, Jasmin Sandhu, Pauline Camacho
OBJECTIVE: Bisphosphonate (BP) drug holidays are recommended to lower the risk of rare adverse events, such as atypical femoral fractures and osteonecrosis of the jaw. However, there are minimal data on the optimal duration of these holidays. Our aim was to determine the clinical and laboratory parameters associated with increased fracture risk in patients on BP drug holiday. METHODS: A retrospective chart review was conducted of 401 patients with osteopenia or osteoporosis who began a BP drug holiday from 2004 to 2013...
November 16, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29143901/combined-vertebral-augmentation-and-radiofrequency-ablation-in-the-management-of-spinal-metastases-an-update
#9
REVIEW
Ning Mao Kam, Julian Maingard, Hong Kuan Kok, Dinesh Ranatunga, Duncan Brooks, William C Torreggiani, Peter L Munk, Michael J Lee, Ronil V Chandra, Hamed Asadi
Spinal metastases are the most commonly encountered tumour of the spine, occurring in up to 40% of patients with cancer. Each year, approximately 5% of cancer patients will develop spinal metastases. This number is expected to increase as the life expectancy of cancer patients increases. Patients with spinal metastases experience severe and frequently debilitating pain, which often decreases their remaining quality of life. With a median survival of less than 1 year, the goals of treatment in spinal metastases are reducing pain, improving or maintaining level of function and providing mechanical stability...
November 16, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29133976/bisphosphonates-atherosclerosis-and-vascular-calcification-update-and-systematic-review-of-clinical-studies
#10
REVIEW
Carla Caffarelli, Andrea Montagnani, Ranuccio Nuti, Stefano Gonnelli
Background: Epidemiologic and clinical data have suggested the existence of a biologic linkage between the bone system and the vascular system. Bisphosphonates (BPs) are effective inhibitors of bone resorption and are currently considered the drugs of choice for the prevention and treatment of osteoporosis and related fractures. Data from several publications have suggested that BPs may also be effective in reducing the atherosclerotic process and vascular calcification, but the results of these studies are contrasting...
2017: Clinical Interventions in Aging
https://www.readbyqxmd.com/read/29132335/topical-zoledronic-acid-decreases-micromotion-induced-bone-resorption-in-a-sheep-arthroplasty-model
#11
Thomas Jakobsen, Søren Kold, Juan Shiguetomi-Medina, Jorgen Baas, Kjeld Soballe, Ole Rahbek
BACKGROUND: Initial micromotion of a total hip replacement is associated with aseptic loosening. The use of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion. Bisphosphonates compounds are inhibitors of bone resorption. The aim of this study was to investigate whether local treatment with bisphosphonate would reduce bone resorption and fibrous tissue around an experimental implant subjected to micromotion. METHODS: One micromotion implant were inserted into each medial femoral condyle in ten sheep...
November 13, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/29130610/the-effects-of-icariin-on-wound-healing-of-extraction-sites-with-administration-of-zoledronic-and-dexamethasone-a-rat-model-study
#12
Jie Liu, Nikos Mattheos, Cheng Su, Chuanxi Deng, Nanyu Luo, Zekun Wang, Hua Tang
OBJECTIVE: This study was intended to investigate the effects of Icariin on the healing of tooth extraction sites under systemic administration of Zoledronic and Dexamethasone. METHOD: Thirty female rats underwent bilateral ovariectomy and were randomly assigned to 5 groups: SS group received weekly injection of saline while ZD, ZD+LICA, ZD+MICA and ZD+HICA groups received Zoledronic with Dexamethasone for 8 weeks. One week later, mandibular first molars were extracted in all groups...
November 11, 2017: Journal of Oral Pathology & Medicine
https://www.readbyqxmd.com/read/29129406/neuropeptide-y-y2-antagonist-treated-ovariectomized-mice-exhibit-greater-bone-mineral-density
#13
K L Seldeen, P G Halley, C H Volmar, M A Rodríguez, M Hernandez, M Pang, S K Carlsson, L J Suva, C Wahlestedt, B R Troen, S P Brothers
Osteoporosis, a disease characterized by progressive bone loss and increased risk of fracture, often results from menopausal loss of estrogen in women. Neuropeptide Y has been shown to negatively regulate bone formation, with amygdala specific deletion of the Y2 receptor resulting in increased bone mass in mice. In this study, ovariectomized (OVX) mice were injected once daily with JNJ-31020028, a brain penetrant Y2 receptor small molecule antagonist to determine the effects on bone formation. Antagonist treated mice had reduced weight and showed increased whole-body bone mineral density compared to vehicle-injected mice...
November 7, 2017: Neuropeptides
https://www.readbyqxmd.com/read/29127574/biologic-treatment-for-chronic-recurrent-multifocal-osteomyelitis-report-of-four-cases-and-review-of-the-literature
#14
REVIEW
Elena Tronconi, Angela Miniaci, Michelangelo Baldazzi, Laura Greco, Andrea Pession
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare non-infectious inflammatory disorder with unpredictable clinical course, characterized by acute exacerbations and spontaneous remissions. There are no randomized-controlled trials about treatment options. Non-steroidal anti-inflammatory drugs (NSAID) are the first-line treatment option; glucocorticoids seem to be effective; positive outcomes have been obtained with bisphosphonates. In the last few years successful use of biologic agents like anti-TNF agents has been reported...
November 11, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29125079/-relapse-of-chronic-inflammatory-demyelinating-polyneuropathy-following-treatment-with-zoledronic-acid
#15
M Loef, E C T Geijteman, K J Beelen, M Bornebroek, D H Schweitzer
BACKGROUND: Zoledronic acid is a nitrogen-containing bisphosphonate that is frequently used in the treatment of osteoporosis. Many patients experience a so-called acute-phase reaction during initial treatment; this is characterized by flu-like symptoms and fever. CASE DESCRIPTION: We describe a 61-year-old woman who suffered from chronic inflammatory demyelinating polyneuropathy (CIDP), and who was started on intravenous zoledronic acid treatment as adjuvant therapy for breast cancer...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/29124881/the-implications-of-baseline-bone-health-assessment-at-initiation-of-androgen-deprivation-therapy-for-prostate-cancer
#16
Peter S Kirk, Tudor Borza, Vahakn B Shahinian, Megan E V Caram, Danil V Makarov, Jeremy B Shelton, John T Leppert, Ryan M Blake, Jennifer A Davis, Brent K Hollenbeck, Anne Sales, Ted A Skolarus
OBJECTIVES: To assess bone density testing (BDT) use among prostate cancer survivors receiving ADT, and downstream implications for osteoporosis and fracture diagnoses as well as pharmacologic osteoporosis treatment in a national integrated delivery system. METHODS: We identified 17,017 men with prostate cancer who received any ADT between 2005 and 2014 using Veterans Health Administration cancer registry and administrative data. We identified claims for BDT within a 3-year period of ADT initiation...
November 10, 2017: BJU International
https://www.readbyqxmd.com/read/29121889/prevalence-and-associated-factors-of-medication-non-adherence-in-hematological-oncological-patients-in-their-home-situation
#17
Linda Bouwman, Corien M Eeltink, Otto Visser, Jeroen J W M Janssen, Jolanda M Maaskant
BACKGROUND: Medication non-adherence is associated with poor health outcomes and increased health care costs. Depending on definitions, reported non-adherence rates in cancer patients ranges between 16 and 100%, which illustrates a serious problem. In malignancy, non-adherence reduces chances of achievement of treatment response and may thereby lead to progression or even relapse. Except for Chronic Myeloid Leukemia (CML), the extent of non-adherence has not been investigated in hematological-oncological patients in an outpatient setting...
November 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29118758/combining-v%C3%AE-9v%C3%AE-2-t-cells-with-a-lipophilic-bisphosphonate-efficiently-kills-activated-hepatic-stellate-cells
#18
Xiaoying Zhou, Yanzheng Gu, Hongying Xiao, Ning Kang, Yonghua Xie, Guangbo Zhang, Yan Shi, Xiaoyu Hu, Eric Oldfield, Xueguang Zhang, Yonghui Zhang
Activated hepatic stellate cells (aHSCs) are now established as a central driver of fibrosis in human liver injury. In the presence of chronic or repeated injury, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) can occur, so there is interest in down-regulating aHSCs activity in order to treat these diseases. Here, we report that Vγ9Vδ2 T cells are reduced in patients with liver cirrhosis, stimulating us to investigate possible interactions between Vγ9Vδ2 T cells and aHSCs. We find that Vγ9Vδ2 T cells kill aHSCs and killing is enhanced when aHSCs are pretreated with BPH-1236, a lipophilic analog of the bone resorption drug zoledronate...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29112802/consensus-treatment-plans-for-chronic-nonbacterial-osteomyelitis-refractory-to-nonsteroidal-anti-inflammatory-drugs-and-or-with-active-spinal-lesions
#19
Yongdong Zhao, Eveline Y Wu, Melissa S Oliver, Ashley M Cooper, Matthew L Basiaga, Sheetal S Vora, Tzielan C Lee, Emily Fox, Gil Amarilyo, Sara M Stern, Jeffrey A Dvergsten, Kathleen A Haines, Kelly A Rouster-Stevens, Karen B Onel, Julie Cherian, Jonathan S Hausmann, Paivi Miettunen, Tania Cellucci, Farzana Nuruzzaman, Angela Taneja, Karyl S Barron, Matthew C Hollander, Sivia K Lapidus, Suzanne C Li, Seza Ozen, Hermann Girschick, Ronald M Laxer, Fatma Dedeoglu, Christian M Hedrich, Polly J Ferguson
OBJECTIVE: To develop standardized treatment regimens for chronic nonbacterial osteomyelitis (CNO), also known as chronic recurrent multifocal osteomyelitis (CRMO) to enable comparative effectiveness treatment studies. METHODS: Virtual and face-to-face discussions and meetings were held within the CNO subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA). A literature search was conducted, and CARRA membership was surveyed to evaluate available treatment data and identify current treatment practices...
November 7, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/29112505/effects-of-bisphosphonates-on-orthodontic-treatment-and-the-tmj-a-systematic-review
#20
Bhumija Gupta, Shilpa Singh, Ross H Tallents, Emile Rossouw
No abstract text is available yet for this article.
August 2017: Journal of Clinical Orthodontics: JCO
keyword
keyword
1525
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"